Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Esperoct (turoctocog alfa pegol) for the Treatment of Haemophilia A

Drug Name

Esperoct® (turoctocog alfa pegol)

Developer

Novo Nordisk

Therapy Class

Anti-haemorrhagic

Product Description

Glycopegylated version of recombinant anti-haemophilic factor

Current Indication

Haemophilia A

Market Sector

Genetics

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top